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Abstract
Introduction: Cardiac amyloidosis is a manifestation of several systemic diseases known as
amyloidoses. Arterial thromboembolic complications have not been reported to occur frequently,
although the pathophysiology of cardiovascular amyloidosis would theoretically predispose to such
manifestations.
Case presentation: We present the case of a 52-year-old woman, who suffered from cardiac
amyloidosis and was admitted to our hospital for left acute limb ischemia. An urgent embolectomy
was performed, improving her clinical condition and the pathologoanatomic examination of the
embolus revealed deposition of amyloid.
Conclusion: Peripheral arterial thromboembolic events in patients with amyloidosis are rare. An
antiplatelet treatment is recommended in such patients with cardiac amyloidosis for the prevention
of embolism.
Introduction
Amyloidosis, despite being a single entity, is a general term
covering a wide range of variable diseases, quite though
uncommon. Data from Olmsted County, Minn, reflect
age-adjusted incidences between 6.1 and 10.5 per million
person-years [1]. It is estimated that 1275 to 3200 new
cases occur annually in the United States [1-3]. Amyloid
disposition can be found in any part of the body
associated with variable non-specific symptoms. Particu-
larly though cardiac involvement is one of the causes
which can lead to death. The usual pathophysiology
involves myocardial infiltration producing slowed
diastolic filling. Less frequently, cardiac amyloid may
simulate cardiomyopathy, congestive heart failure, coronary
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thromboembolism is an unusual phenomenon in cardiac
amyloidosis. Investigation of contributing causes reveals
disorders producing stasis, endothelial disturbance and
probablyabnormalitiesinbloodcoagulability[4].Weherein
present a patient with amyloid heart disease complicated by
cardiogenic systemic arterial thromboembolism.
Case presentation
A 52-year-old Greek woman was transferred to the
Emergency Unit of our Hospital with symptoms of acute
left-limb ischemia. The patient reported sudden onset of
calf pain, starting five days before. Symptoms rapidly
deteriorated on admission day. The clinical examination
revealed a cold, pale and painful left leg with absent
peripheral pulses but normal ones on the right. The
patient was in good general condition, the pulse was
67/min, the arterial blood pressure was 100/50 mmHg
and lung examination did not reveal any particular
findings. The EKG showed low voltage without atrial
fibrillation. Her past medical history indicated cardiac
insufficiency due to amyloidosis. A past echocardiogram
had revealed restrictive cardiomyopathy with hypertrophy
of the left ventricular wall and two years ago myocardial
biopsy had shown positive histochemical stains for red of
Congo and positive immunohistochemical staining for
serum amyloid P component and lamda light chains
indicative of primary amyloidosis (AL). As the biopsy was
performed elsewhere, adequate information for the site of
ventricle punctured, do not exist. An urgent embolectomy
was performed following intravenous administration of
5000 IU heparin. Histology of the embolus revealed
amyloidosis (Figure 1 & Figure 2). Postoperatively,
intravenous heparin and per os anticoagulants (warfarin)
were administered. Alongside, low doses of inotropes were
required to maintain adequate blood pressure. A new
echocardiogram revealed good myocardial function with
diastolic dysfunction, calcification of the valves, mild
mitral, tricuspidal and aortic valve insufficiency, while also
hypertrophy of the left ventricle and restrictive amyloid
cardiomyopathy. The patient was discharged on the 6th
postoperative day in good general condition. Three
months later oral anticoagulants were discontinued and
low dose of aspirin (100 mg/day) was prescribed. To date
the patient has not presented any type of recurrence.
Discussion
The exact mechanism by which aggregation of amyloidosis
causes damage and consequent dysfunction has been
widely studied and discussed. The cardiovascular system is
among the common targets of amyloidosis [5]. In clinical
practice, amyloidosis is categorized in primary, secondary
and hereditary. Primary (idiopathic, systemic) presents
without previous or coexisting disease; it may involve the
cardiovascular system, the gastrointestinal tract and the
muscles. Secondary amyloidosis is linked to chronic
diseases and has a tendency to target parenchymal organs
such as the liver, spleen, and kidneys [6]. Regarding the
heart symptoms of amyloidosis are not concrete. Cardiac
amyloidosis can mimic cardiomyopathy, coronary cardiac
disease, valvular cardiac disease or arrhythmia. The most
common clinical feature though is right cardiac insuffi-
ciency, while coronary artery disease manifests predomi-
nantly in men by 60-65%, and only 1% of patients are
younger than 40 years [7]. Concerning the natural history
of thromboembolic disease in patients with amyloidosis,
the medical files of 2.132 patients were evaluated in the
Figure 1. Partial deposition of amorphous eosinifilic
substance in the vascular wall (H&E ×400).
Figure 2. Deposition of amorphous eosinifilic substance,
doubledirectioninpolarizedlight(coloured:CongoRed×400,
compatible with amyloid).
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(21 men, median age 65) were selected to objectively
evaluate the incidence of thromboembolic disease. Twelve
patients had cardiac amyloidosis and 20 had kidney
amyloidosis. Neither the extent of amyloidosis nor the
type of monoclonal protein was predictive of thrombo-
embolism. Thromboembolism manifested before the
diagnosis of amyloidosis in 11 patients, during the
diagnosis or within a month after the diagnosis in
11 patients, and one month or more following diagnosis
in 18 patients. Twenty nine patients (73%) had vein
thrombosis and 11 (28%) had arterial thrombosis. Eight
patients (20%) died within a month after the thrombotic
formation, and 18 (45%) died within a year. Thrombo-
emboliceventsinpatientswithALamyloidosisanticipated
a significant mortality within the first year following the
event[8].Thepatientswithcardiacamyloidosispresenteda
cardiac insufficiency with impaired diastolic function
despitesatisfactorysystolicfunction.Suchpatients,though
rarely, can develop cardiogenic thromboembolic disease.
The rarity of this complication is impressive taking into
consideration the pathophysiological basis of cardiac
amyloidosis. Research into the contributing causes reveals
that events present on the basis of the classic Virchow triad
involving disturbance of blood flow, endothelial damage
and possible abnormalities of blood coagulability. These
facts lead to concrete proposals for prophylaxis and
management of the diseased population [9].
Cardiac amyloidosis is considered a potential cause of
systemic embolism. Nevertheless, such events have not
been frequently reported. Cardiac mural clot is common
in autopsies of patients with amyloidosis. Recommended
diagnostic assessment is transoesophageal cardiac ultra-
sound to investigate clots within the endocardium. On
such high likelihood of thromboembolic episodes, anti-
coagulation treatment as a preventive measure should be
considered. Low-dose aspirin appears to be safer for
thromboprofylaxis than the use of warfarin [4].
Conclusions
Even if amyloidosis is a complex disease, it complies with
the triad of Virchow and predisposes the patients to
thromboembolic events. This case report presents such an
infrequentincidenceinapatientwhosufferedfromcardiac
amyloidosis complicated by a thromboembolic episode of
the lower limb. For such cases, we advocate thrombopro-
fylaxis with low-dose (100 mg/day) aspirin. In patients
with atrial fibrillation or arrhythmias we should consider
administering anticoagulants (e.g. vitamin K antagonists)
in therapeutic doses (INR 2.0-2.5).
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